AQUINO-JARQUING., TOSCANO-GARIBAYJ.D.2011. RNA Aptamer evolution: two decades of SELEction. Int. J. Mol. Sci., 12:9155–9171.
2.
ARNOLDS., PAMPALAKISG., KANTIOTOUK., SILVAD., CORTEZC., MISSAILIDISS., SOTIROPOULOUG.2012. One round of SELEX for the generation of DNA aptamers directed against KLK6. Biol. Chem., 393:343–353.
3.
CROUZIERL., DUBOISC., EDWARDSS.L., LAURIDSENL.H., WENGELJ., VEEDUR.N.2012. Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers. PLoS One, 7:e35990.
DRABOVICHA.P., BEREZOVSKIM., OKHONINV., KRYLOVS.N.2006. Selection of smart aptamers by methods of kinetic capillary electrophoresis. Anal. Chem., 78:3171–3178.
6.
ELLINGTONA.D., SZOSTAKJ.W.1990. In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
7.
EULBERGD., BUCHNERK., MAASCHC., KLUSSMANNS.2005. Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res., 33:e45.
8.
FAMULOKM.2009. Exploring Chemical Space with Aptamers. J. Med. Chem., 52:6951–6957.
9.
FÖRSTERC., ZYDEKM., ROTHKEGELM., WUZ.Y., GALLINC., GESSNERR., LISDATF., FÜRSTEJ.P.2012. Properties of an ‘LNA’-modified ricin RNA aptamer. Biochem. Biophys. Res. Commun., 419:60–65.
HERNANDEZF.J., KALRAN., WENGELJ., VESTERB.2009. Aptamers as a model for functional evaluation of LNA and 2′-amino LNA. Bioorg. Med. Chem. Lett., 19:6585–6587.
12.
IMANISHIT., OBIKAS.2002. BNAs: novel nucleic acid analogs with a bridged sugar moiety. Chem. Commun., 1653–1659.
13.
JEPSENJ.S., WENGELJ.2004. LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discovery Dev., 7:188–194.
14.
KASAHARAY., KITADUMES., MORIHIROK., KUWAHARAM., OZAKIH., SAWAIH., IMANISHIT., OBIKAS.2010. Effect of 3′-end capping of aptamer with various 2′,4′-bridged nucleotides: Enzymatic post-modification toward a practical use of polyclonal aptamers. Bioorg. Med. Chem. Lett., 20:1626–1629.
15.
KEEFEA.D., PAIS., ELLINGTONA.2010. Aptamers as therapeutics. Nat. Rev. Drug Discovery, 9:537–550.
16.
KUWAHARAM., OBIKAS., NAGASHIMAJ., OHTAY., SUTOY., OZAKIH., SAWAIH., IMANISHIT.2008. Systematic analysis of enzymatic DNA polymerization using oligo-DNA templates and triphosphate analogs involving 2′,4′-bridged nucleosides. Nucleic Acids Res., 36:4257–4265.
17.
LANFORDR.E., HILDEBRANDT-ERIKSENE.S., PETRIA., PERSSONR., LINDOWM., MUNKM.E., KAUPPINENS., ORUMH.2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 327:198–201.
18.
LAURIDSENL.H., ROTHNAGELJ.A., VeeduR.N.2012. Enzymatic recognition of 2′-modified ribonucleoside 5′-triphosphates: towards the evolution of versatile aptamers. ChemBioChem, 13:19–25.
19.
MALLIKARATCHYP.R., RUGGIEROA., GARDNERJ.R., KURYAVYIV., MAGUIREW.F., HEANEYM.L., MCDEVITTM.R., PATELD.J., SCHEINBERGD.A.2011. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res., 39:2458–2469.
20.
MAYERG.2009. The chemical biology of aptamers. Angew. Chem. Int. Ed., 48:2672–2689.
21.
NITSCHEA., KURTHA., DUNKHORSTA., PÄNKEO., SIELAFFH., JUNGEW., MUTHD., SCHELLERF., STÖCKLEINW., DAHMENC.et al.2007. One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol., 7:48.
SCHMIDTK.S., BORKOWSKIS., KURRECKJ., STEPHENSA.W., BALDR., HECHTM., FRIEBEM., DINKELBORGL., ERDMANNV.A.2004. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res., 32:5757–5765.
24.
SHANGGUAND., TANGZ.W., MALLIKARATCHYP., XIAOZ.Y., TANW.H.2007. Optimization and modifications of aptamers selected from live cancer cell lines. ChemBioChem, 8:603–606.
25.
TAKENAKAH., YOSHIDAY., HORIIK., FURUICHIM., YAGIH., AKITOMIJ., YAMAGUCHIM., KATOUS., NISHIKATAK., WAGAI.2011. Preparations of aptamer nucleic acids having binding affinities to immunoglobulin G derived from rodents and their analytical applications. PCT Int.Appl. No. WO2011021308A1.
26.
THIELK.W.2009. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides, 19:209–222.
27.
TUERKC., GOLDL.1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage-T4 DNA-polymerase. Science, 249:505–510.
28.
VEEDUR.N., VESTERB., WENGELJ.2007a. Enzymatic incorporation of LNA nucleotides into DNA strands. ChemBioChem, 8:490–492.
29.
VEEDUR.N., VESTERB., WENGELJ.2007b. In vitro incorporation of LNA nucleotides. Nucleosides Nucleotides Nucleic Acids, 26:1207–1210.
VEEDUR.N., VESTERB., WENGELJ.2008. Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates. J. Am. Chem. Soc., 130:8124–8125.
32.
VEEDUR.N., VESTERB., WENGELJ.2009. Efficient enzymatic synthesis of LNA-modified DNA duplexes using KOD DNA polymerase. Org. Biomol. Chem., 7:1404–1409.
33.
VEEDUR.N., VESTERB., WENGELJ.2010. Polymerase directed incorporation studies of LNA-G nucleoside 5′-triphosphate and primer extension involving all four LNA nucleotides. New J. Chem., 34:877–879.
34.
VEEDUR.N., WENGELJ.2009. Locked nucleic acid nucleoside triphosphates and polymerases: on the way towards evolution of LNA aptamers. Mol. BioSyst., 5:787–792.
VERONESEF.M., PASUTG.2005. PEGylation, successful approach to drug delivery. Drug Discov. Today, 10:1451–1458.
37.
WOCHNERA., CECHB., MENGERM., ERDMANNV.A., GLÖKLERJ.2007. Semi-automated selection of DNA aptamers using magnetic particle handling. BioTechniques, 43:344–353.
